Arno Therapeutics S-1/A 1 Apr 16 IPO registration (amended) Financial data

Document And Entity Information

Document And Entity Information	12 Months Ended
	Dec. 31, 2015
Document Information [Line Items]
Document Type	S1
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Entity Registrant Name	Arno Therapeutics, Inc
Entity Central Index Key	1,195,116
Entity Filer Category	Smaller Reporting Company

BALANCE SHEETS

BALANCE SHEETS - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Current assets
Cash and cash equivalents	$ 66,988	$ 7,948,436
Prepaid expenses and other current assets	260,694	258,046
Total current assets	327,682	8,206,482
Property and equipment, net	23,103	30,730
Security deposit	10,455	10,455
Total assets	361,240	8,247,667
Current liabilities
Accounts payable	1,010,215	742,448
Accrued expenses and other current liabilities	1,124,690	1,410,293
Convertible notes, net of financing costs of $10,091	2,089,909	0
Capital lease obligation- short term	3,853	3,322
Deferred rent	1,910	1,048
Total current liabilities	4,230,577	2,157,111
Capital lease obligation- long term	4,070	7,923
Derivative liabilities	4,750,687	6,671,524
Total liabilities	$ 8,985,334	$ 8,836,558
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS’ DEFICIT
Preferred stock, $0.0001 par value, 35,000,000 shares authorized, none issued and outstanding	$ 0	$ 0
Common stock, $0.0001 par value, 500,000,000 shares authorized, 20,408,616 shares issued and outstanding at December 31, 2015 and December 31, 2014, respectively	5,469	5,469
Additional paid-in capital	84,665,390	81,192,630
Accumulated deficit	(93,294,953)	(81,786,990)
Total stockholders’ deficit	(8,624,094)	(588,891)
Total liabilities and stockholders’ deficit	$ 361,240	$ 8,247,667

BALANCE SHEETS (Parenthetical)

BALANCE SHEETS (Parenthetical) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Unamortized Debt Issuance Expense	$ 10,091
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	35,000,000	35,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	20,408,616	20,408,616
Common stock, shares outstanding	20,408,616	20,408,616

STATEMENTS OF OPERATIONS

STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Operating expenses:
Research and development	$ 8,653,008	$ 14,840,302
General and administrative	4,758,803	6,653,024
Total operating expenses	13,411,811	21,493,326
Loss from operations	(13,411,811)	(21,493,326)
Other income/(expense):
Interest income	7,658	41,954
Interest expense	(28,403)	(143)
Other income, net	1,924,593	29,222,282
Total other income/(expense)	1,903,848	29,264,093
Net income/(loss)	$ (11,507,963)	$ 7,770,767
Net income/(loss) per share - basic	$ (0.56)	$ 0.38
Weighted-average shares outstanding- basic	20,408,616	20,381,554
Net income/(loss) per share - diluted	$ (0.56)	$ 0.31
Weighted-average shares outstanding- diluted	20,408,616	24,809,995

STATEMENT OF STOCKHOLDERS' (DEF

STATEMENT OF STOCKHOLDERS' (DEFICIT) EQUITY - USD ($)	Total	PREFERRED STOCK	COMMON STOCK	ADDITIONAL PAID-IN CAPITAL	ACCUMULATED DEFICIT
Balance at Dec. 31, 2013	$ (12,883,326)	$ 0	$ 5,465	$ 76,668,966	$ (89,557,757)
Balance (in shares) at Dec. 31, 2013		0	20,370,331
Net income loss	7,770,767	$ 0	$ 0	0	7,770,767
Stock based compensation for services	4,523,668	0	0	4,523,668	0
Issuance of common stock	0	$ 0	$ 4	(4)
Issuance of common stock (in shares)		0	38,285
Balance at Dec. 31, 2014	(588,891)	$ 0	$ 5,469	81,192,630	(81,786,990)
Balance (in shares) at Dec. 31, 2014		0	20,408,616
Net income loss	(11,507,963)	$ 0	$ 0	0	(11,507,963)
Stock based compensation for services	3,472,760	0	0	3,472,760	0
Balance at Dec. 31, 2015	$ (8,624,094)	$ 0	$ 5,469	$ 84,665,390	$ (93,294,953)
Balance (in shares) at Dec. 31, 2015		0	20,408,616

STATEMENTS OF CASH FLOWS

STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities:
Net income/(loss)	$ (11,507,963)	$ 7,770,767
Adjustment to reconcile net income/(loss) to net cash and cash equivalents used in operating activities:
Depreciation and amortization	7,627	12,586
Stock-based compensation	3,472,760	4,523,668
Change in fair value of derivative liability	(1,920,837)	(29,193,357)
Amortization of financing costs	2,437
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(2,648)	(171,780)
Accounts payable	267,767	(2,199,550)
Accrued expenses	(285,603)	485,038
Deferred rent	862	(6,749)
Due to related party	0	(26,039)
Net cash used in operating activities	(9,965,598)	(18,805,416)
Cash flows from investing activities:
Purchase of property and equipment	0	(20,096)
Net cash used in investing activities	0	(20,096)
Cash flows from financing activities:
Payment of capital lease obligation	(3,322)	(255)
Convertible notes financing issuance costs	(12,528)	0
Proceeds from issuance of convertible notes payable	2,100,000	0
Net cash provided by financing activities	2,084,150	(255)
Net decrease in cash and cash equivalents	(7,881,448)	(18,825,767)
Cash and cash equivalents at beginning of period	7,948,436	26,774,203
Cash and cash equivalents at end of period	66,988	7,948,436
Supplemental schedule of cash flows information:
Cash paid for interest	1,139	143
Supplemental schedule of non-cash investing and financing activities:
Acquisition of equipment pursuant to capital leases	$ 0	$ 11,500

DESCRIPTION OF BUSINESS

DESCRIPTION OF BUSINESS	12 Months Ended
	Dec. 31, 2015
Business Combination, Description [Abstract]
DESCRIPTION OF BUSINESS	1. DESCRIPTION OF BUSINESS Arno Therapeutics, Inc. (“Arno” or the “Company”) is developing innovative drug candidates intended to treat patients with cancer and other life threatening diseases. The Company was incorporated in Delaware in March 2000, at which time its name was Laurier International, Inc. (“Laurier”). Pursuant to an Agreement and Plan of Merger dated March 6, 2008 (as amended, the “Merger Agreement”), by and among the Company, Arno Therapeutics, Inc., a Delaware corporation formed on August 1, 2005 (“Old Arno”), and Laurier Acquisition, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Laurier Acquisition”), on June 3, 2008, Laurier Acquisition merged with and into Old Arno, with Old Arno remaining as the surviving corporation and a wholly-owned subsidiary of Laurier. Immediately following this merger, Old Arno merged with and into Laurier and Laurier’s name was changed to Arno Therapeutics, Inc. These two merger transactions are hereinafter collectively referred to as the “Merger.” Immediately following the Merger, the former stockholders of Old Arno collectively held 95

LIQUIDITY AND CAPITAL RESOURCES

LIQUIDITY AND CAPITAL RESOURCES	12 Months Ended
	Dec. 31, 2015
Working Capital Information [Abstract]
LIQUIDITY AND CAPITAL RESOURCES	2. LIQUIDITY AND CAPITAL RESOURCES Cash resources as of December 31, 2015 were approximately $ 0.1 7.9 The long-term success of the Company depends on its ability to develop new products to the point of regulatory approval and subsequent revenue generation and, accordingly, to raise enough capital to finance these developmental efforts. Management plans to raise additional capital either by selling shares of its stock or other securities, issuing additional indebtedness or by licensing the rights to one or more of its product candidates to finance the continued operating and capital requirements of the Company. Amounts raised will be used to further develop the Company’s product candidates, acquire rights to additional product candidates and for other working capital purposes. While the Company will extend its best efforts to raise additional capital to fund all operations through May 2016 and beyond, management can provide no assurances that the Company will be successful in raising sufficient funds. In addition, to the extent that the Company raises additional funds by issuing shares of its common stock or other securities convertible or exchangeable for shares of common stock, stockholders will experience dilution, which may be significant. In the event the Company raises additional capital through debt financings, the Company may incur significant interest expense and become subject to covenants in the related transaction documentation that may affect the manner in which the Company conducts its business. To the extent that the Company raises additional funds through collaboration and licensing arrangements, it may be necessary to relinquish some rights to its technologies or product candidates, or grant licenses on terms that may not be favorable to the Company. Any or all of the foregoing may have a material adverse effect on the Company’s business and financial performance. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company’s financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The financial statements do not include any adjustments that might result from the inability of the Company to continue as a going concern.

THE MERGER AND BASIS OF PRESENT

THE MERGER AND BASIS OF PRESENTATION	12 Months Ended
	Dec. 31, 2015
Mergers Acquisitions And Dispositions Disclosures [Abstract]
THE MERGER AND BASIS OF PRESENTATION	3. THE MERGER AND BASIS OF PRESENTATION The accompanying audited financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and the instructions to Form 10-K promulgated by the Securities and Exchange Commission (“SEC”). (a) Description of the Merger and Private Placement Offering The Company completed the Merger on June 3, 2008. In accordance with the terms of the Merger, each share of common stock of Old Arno that was outstanding immediately prior to the Merger was exchanged for 1.99377 1,611,760 19,291,824 1,100,200 95 Following the Merger, the business conducted by the Company is the business conducted by Old Arno prior to the Merger. In addition, the directors and officers of Laurier were replaced by the directors and officers of Old Arno. As a condition and immediately prior to the closing of the Merger, on June 2, 2008, Old Arno completed a private placement of its equity securities whereby it received gross proceeds of approximately $ 17,732,000 3,691,900 7,360,700 6 984,246 98,409 4.83 1,962,338 196,189 2.42 All references to share and per share amounts in these financial statements have been restated to retroactively reflect the number of common shares of Arno common stock issued pursuant to the Merger. (b) Accounting Treatment of the Merger; Financial Statement Presentation The Merger was accounted for as a reverse acquisition pursuant to Accounting Standards Codification (“ASC”) 805-40-25, which provides that the “merger of a private operating company into a non-operating public shell corporation with nominal net assets typically results in the owners and management of the private company having actual or effective operating control of the combined company after the transaction, with the shareholders of the former public shell continuing only as passive investors. These transactions are considered by the Securities and Exchange Commission to be capital transactions in substance, rather than business combinations. That is, the transaction is equivalent to the issuance of stock by the private company for the net monetary assets of the shell corporation, accompanied by a recapitalization.” Accordingly, the Merger has been accounted for as a recapitalization, and, for accounting purposes, Old Arno is considered the acquirer in a reverse acquisition. Laurier’s historical accumulated deficit for periods prior to June 3, 2008, in the amount of $ 120,538 Because the Merger was accounted for as a reverse acquisition under GAAP, the financial statements for periods prior to June 3, 2008 reflect only the operations of Old Arno. (c) Reverse Stock Split Effective as of the close of business on October 29, 2013, the Company amended its Amended and Restated Certificate of Incorporation to effect a combination (“Reverse Stock Split”) of the Common Stock at a ratio of one-for-eight. All historical share and per share amounts have been adjusted to reflect the Reverse Stock Split.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The preparation of financial statements in conformity with GAAP requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Estimates and assumptions principally relate to services performed by third parties but not yet invoiced, estimates of the fair value and forfeiture rates of stock options issued to employees, directors and consultants, valuation of derivatives and estimates of the probability and potential magnitude of contingent liabilities. Actual results could differ from those estimates. The Company considers all highly liquid investments with a remaining maturity of three months or less at the time of acquisition to be cash equivalents. Finance costs relating to the convertible notes issued are recorded as a direct reduction of the liability and amortized to interest expense over the expected term using the effective interest method. Prepaid expenses consist of payments made in advance to vendors relating to service contracts for clinical trial development, insurance policies and license fees. These advanced payments are amortized to expense either as services are performed or over the relevant service period using the straight line method. Property and equipment consist primarily of furnishings, fixtures, leasehold improvements and computer equipment and are recorded at cost. Repairs and maintenance costs are expensed in the period incurred. Depreciation of property and equipment is provided for by the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized using the straight-line method over the remaining lease term or the life of the asset, whichever is shorter. Description Estimated Useful Life Office equipment and furniture 5 to 7 years Leasehold improvements 3 years Computer equipment 3 years Equipment under capitalized lease Over life of lease The Company measures fair value in accordance with generally accepted accounting principles. Fair value measurements are applied under other accounting pronouncements that require or permit fair value measurements. Financial instruments included in the Company’s balance sheets consist of cash and cash equivalents, accounts payable, accrued expenses, due to related parties, and derivative liability. The carrying amounts of these instruments reasonably approximate their fair values due to their short-term maturities. The Company accounts for the convertible debentures and warrants issued in connection with the 2013 Purchase Agreement, the 2012 Purchase Agreement and the 2010 Purchase Agreement (see Note 10) in accordance with the guidance on Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, which provides that the Company classify the warrant instrument as a liability at its fair value and adjusts the instrument to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized as a component of other income or expense. The fair value of warrants issued by the Company, in connection with private placements of securities, has been estimated using a Monte Carlo simulation model and, in doing so, the Company’s management utilized a third-party valuation report. The Monte Carlo simulation is a generally accepted statistical method used to generate a defined number of stock price paths in order to develop a reasonable estimate of the range of the Company’s future expected stock prices and minimizes standard error. Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company deposits cash and cash equivalents with high credit quality financial institutions and is insured to the maximum limitations. Balances in these accounts may exceed federally insured limits at times, which expose the Company to institutional risk. Research and development costs are charged to expense as incurred. Research and development includes employee costs, fees associated with operational consultants, contract clinical research organizations, contract manufacturing organizations, clinical site fees, contract laboratory research organizations, contract central testing laboratories, licensing activities, and allocated executive, human resources and facilities expenses. The Company accrues for costs incurred as the services are being provided by monitoring the status of the trial and the invoices received from its external service providers. As actual costs become known, the Company adjusts its accruals in the period when actual costs become known. Costs related to the acquisition of technology rights and patents for which development work is still in process are charged to operations as incurred and considered a component of research and development expense. Stock-based compensation cost is measured at the grant date based on the value of the award and is recognized as expense over the required service period, which is generally equal to the vesting period. Share-based compensation is recognized only for those awards that are ultimately expected to vest. Common stock, stock options or other equity instruments issued to non-employees (including consultants and all members of the Company’s Scientific Advisory Board) as consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued (unless the fair value of the consideration received can be more reliably measured). The fair value of stock options is determined using the Black-Scholes option-pricing model. The fair value of any options issued to non-employees is recorded as expense over the applicable service periods. Basic net income/(loss) per share is calculated based on the weighted-average number of shares of common stock outstanding during the period. Diluted net income per share is calculated based on the weighted-average number of shares of common stock and other dilutive securities outstanding during the period. The potential dilutive shares of common stock resulting from the assumed exercise of stock options and warrants are determined under the treasury stock method. Year Ended December 31, 2015 2014 Numerator: Net income/(loss) $ (11,507,963) $ 7,770,767 Denominator: Weighted-average shares of common stock outstanding used in the calculation of basic net income/(loss) per share 20,408,616 20,381,554 Effect of dilutive securities: Warrants to purchase common stock - 4,428,441 Weighted-average shares of common stock outstanding used in the calculation of diluted net income/(loss) per share 20,408,616 24,809,995 For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive. Year Ended December 31, 2015 2014 Warrants to purchase common stock 4,455,231 4,455,231 For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted net income/(loss) per share if their effect is anti-dilutive. In addition to the potentially dilutive securities, the aggregate number of common equivalent shares (related to options, warrants and convertible debentures) that have been excluded from the computations of diluted net income/(loss) per common share at December 31, 2015 and 2014 were 30,563,107 50,867,639 The Company has no components of other comprehensive loss other than its net loss, and accordingly, comprehensive loss is equal to net loss for all periods presented. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the period in which the differences are expected to affect taxable income. The Company provides a valuation allowance when it appears more likely than not that some or all of the net deferred tax assets will not be realized. The Company has not performed an Internal Revenue Section 382 limitation study. Depending on the outcome of such study, the gross amount of net operating losses recognized in future tax periods could be limited. A tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The Company’s policy is to include interest and penalties related to unrecognized tax benefits within the Company’s provision for (benefit from) income taxes. The Company recognized no amounts for interest and penalties related to unrecognized tax benefits in 2015 and 2014 respectively. In addition, the Company had no amounts accrued for interest and penalties as of December 31, 2015 and 2014, respectively. In August 2014, the FASB issued Accounting Standards Update No. 2014-15, “Presentation of Financial Statements- Going Concern (Topic 205-40)” (“ASU 2014-15”). Under the standard, management is required to evaluate for each annual and interim reporting period whether it is a probable that the entity will not be able to meet its obligations as they become due within one year after the date that financial statements are issued, or are available to be issued, where applicable. ASU 2014-15 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016, and early adoption is permitted. Accordingly, the standard is effective for the Company on January 1, 2017. The Company will be evaluating the impact, if any, that the standard will have on its financial condition, results of operations, and disclosures in the near future. In April 2015, the FASB issued Accounting Standards Update No. 2015-03, “Interest- Imputation of Interest (Subtopic 835-30)” (“ASU 2015-03”). This standard requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. ASU 2015-03 is effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those years. Accordingly, the standard is effective for the Company on December 15, 2015. The Company adopted ASU 2015-03 as for the fiscal year 2015 and has reported financing costs as a direct reduction from the carrying amount of convertible notes. The Company’s addition of the standard did not have a material impact on its financial condition, results of operations and disclosures. In November 2015, the FASB issued Accounting Standards Update No. 2015-17, “Balance Sheet Classification of Deferred Taxes” (“ASU 2015-17”). The new standard requires all companies to prospectively classify all deferred tax assets and liabilities as noncurrent on the balance sheet. ASU 2015-17 will be effective for public entities on January 1, 2017. However, early adoption is permitted. The Company is evaluating the potential impact of adopting this standard on its financial statements. In January 2016, the FASB issued Accounting Standards Update No. 2016-01, “Financial Instruments” (“ASU 2016-01”). Equity investments not accounted for under the equity method of accounting will be measured at fair value, with changes in fair value recognized in current earnings. ASU 2016-01 becomes effective for fiscal years beginning after December 15, 2017. Early adoption is permitted provided that the guidance is applied from the beginning of the fiscal year of adoption. The Company does not believe the adoption of this standard will have a material impact on its financial statements, results of operations or related financial statement disclosures. In February 2016, the FASB issued Accounting Standards Update No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). Leasees will need to recognize virtually all of their leases on the balance sheet, by recording a right-of-use asset and lease liability. ASU 2016-02 becomes effective for the Company on January 1, 2019, and early adoption is permitted upon issuance.

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	5. PROPERTY AND EQUIPMENT Property and equipment as of December 31, 2015 and 2014 consist of the following: 2015 2014 Computer equipment and software $ 17,721 $ 17,721 Office furniture and equipment 72,338 72,338 Leasehold improvements 8,449 8,449 Capital leases- equipment 11,500 11,500 Total property and equipment 110,008 110,008 Accumulated depreciation (86,905) (79,278) Total property and equipment, net $ 23,103 $ 30,730 Depreciation expense for the years ended December 31, 2015 and 2014 was $ 7,627 12,586

INTANGIBLE ASSETS AND INTELLECT

INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY	12 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY	6. INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY License Agreements Onapristone License Agreement The Company’s rights to onapristone are governed by a license agreement with Invivis Pharmaceuticals, Inc. (“Invivis”), dated February 13, 2012. Under this agreement, the Company holds an exclusive, royalty-bearing license for the rights to commercialize onapristone for all therapeutic uses. The license agreement provides the Company with worldwide rights to develop and commercialize onapristone with the exception of France; provided, that the Company has an option to acquire French commercial rights from Invivis upon notice to Invivis together with additional consideration. The onapristone license agreement provides the Company with exclusive, worldwide rights to a United States provisional patent application that relates to assays for predictive biomarkers for anti-progestin efficacy. The Company intends to expand its patent portfolio by filing additional patent applications covering the use of onapristone and/or a companion diagnostic product. If the pending patent application issues, the issued patent would be scheduled to expire in 2031. The Company made a one-time cash payment of $ 500,000 15.1 150,000 100,000 350,000 70,833 50,000 Under the license agreement with Invivis, the Company also agreed to indemnify and hold Invivis and its affiliates harmless from any and all claims arising out of or in connection with the production, manufacture, sale, use, lease, consumption or advertisement of onapristone, provided, however, that the Company shall have no obligation to indemnify Invivis for claims that (a) any patent rights infringe third party intellectual property, (b) arise out of the gross negligence or willful misconduct of Invivis, or (c) result from a breach of any representation, warranty confidentiality obligation of Invivis under the license agreement. The license agreement will terminate upon the later of (i) the last to expire valid claim contained in the patent rights, and (ii) February 13, 2032 90 90 AR-12 and AR-42 License Agreements The Company’s rights to both AR-12 and AR-42 are governed by separate license agreements with The Ohio State University Research Foundation (“Ohio State”) entered into in January 2008. Pursuant to each of these agreements, Ohio State granted the Company exclusive, worldwide, royalty-bearing licenses to commercialize certain patent applications, know-how and improvements relating to AR-12 and AR-42 for all therapeutic uses. In 2008, pursuant to the Company’s license agreements for AR-12 and AR-42, the Company made one-time cash payments to Ohio State in the aggregate amount of $ 450,000 6.1 5.0 5.1 4.0 The license agreements with Ohio State further provide that the Company will indemnify Ohio State from any and all claims arising out of the death of or injury to any person or persons or out of any damage to property, or resulting from the production, manufacture, sale, use, lease, consumption or advertisement of either AR-12 or AR-42, except to the extent that any such claim arises out of the gross negligence or willful misconduct of Ohio State. The license agreements for AR-12 and AR-42 each expire on the later of (i) the expiration of the last valid claim contained in any licensed patent and (ii) 20 90 90

ACCRUED LIABILITIES

ACCRUED LIABILITIES	12 Months Ended
	Dec. 31, 2015
Payables and Accruals [Abstract]
ACCRUED LIABILITIES	7. ACCRUED LIABILITIES 2015 2014 Accrued research and development expenses $ 902,723 $ 744,240 Accrued compensation and related benefits 197,457 407,497 Accrued severance - 250,605 Accrued interest on convertible notes 24,510 - Accrued other expenses - 7,951 $ 1,124,690 $ 1,410,293

CONVERTIBLE NOTES PAYABLE

CONVERTIBLE NOTES PAYABLE	12 Months Ended
	Dec. 31, 2015
Convertible Notes Payable [Abstract]
CONVERTIBLE NOTES PAYABLE	8. CONVERTIBLE NOTES PAYABLE On October 21, 2015, the Company issued a 6% convertible promissory note (the “6% Note”) in the principal amount of $ 2,100,000 6 3,500,000 2,100,000 12,528 Unamortized Debt Net Carrying Principal Issuance Costs Amount 6% convertible notes, due October 21, 2016 $ 2,100,000 $ 10,091 $ 2,089,909 As of December 31, 2015, the Company had $ 24,510

FAIR VALUE OF FINANCIAL INSTRUM

FAIR VALUE OF FINANCIAL INSTRUMENTS	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
FAIR VALUE OF FINANCIAL INSTRUMENTS	9. FAIR VALUE OF FINANCIAL INSTRUMENTS The Company defines fair value as the amount at which an asset (or liability) could be bought (or incurred) or sold (or settled) in a current transaction between willing parties, that is, other than in a forced or liquidation sale. The fair value estimates presented in the table below are based on information available to the Company as of December 31, 2015. The accounting standard regarding fair value measurements discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The standard utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: • Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. • Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. • Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions. The Company has determined the fair value of certain liabilities using the market approach. Quoted Market Prices in Active Significant Other Significant Other Fair Value Markets Observable Inputs Unobservable Inputs December 31, 2015 (Level 1) (Level 2) (Level 3) Liabilities: Warrant liability - 2012 Series A $ 1,753,969 $ - $ - $ 1,753,969 Warrant liability - 2012 placement agent 7,661 - - 7,661 Warrant liability - 2013 Series D 2,985,512 - - 2,985,512 Warrant liability - 2013 placement agent 3,545 - - 3,545 Total $ 4,750,687 $ - $ - $ 4,750,687 The following table presents the Company’s fair value hierarchy for these assets measured at fair value on a recurring basis as of December 31, 2014: Quoted Market Prices in Active Significant Other Significant Other Fair Value Markets Observable Inputs Unobservable Inputs December 31, 2014 (Level 1) (Level 2) (Level 3) Liabilities: Warrant liability - 2010 Class B $ 28,066 $ - $ - $ 28,066 Warrant liability - 2012 Series A&B 3,520,319 - - 3,520,319 Warrant liability - 2012 placement agent 67,246 - - 67,246 Warrant liability - 2013 Series D&E 3,036,986 - - 3,036,986 Warrant liability - 2013 placement agent 18,907 - - 18,907 Total $ 6,671,524 $ - $ - $ 6,671,524 Fair Value Measurement Using Significant Unobservable Inputs (Level 3) Total 2013 2012 Warrant 2013 2013 Placement 2012 2012 Placement 2010 Liability Series E Series D Agent Series B Series A Agent Class B Balance at January 1, 2014 $ 35,864,881 $ 5,855,206 $ 12,482,527 $ 98,080 $ 2,816,676 $ 13,887,307 $ 362,633 $ 362,452 Total gains or losses: Unrealized appreciation (29,193,357) (5,829,469) (9,471,278) (79,173) (2,804,295) (10,379,369) (295,387) (334,386) Balance at December 31, 2014 $ 6,671,524 $ 25,737 $ 3,011,249 $ 18,907 $ 12,381 $ 3,507,938 $ 67,246 $ 28,066 Total gains or losses: Unrealized appreciation (1,920,837) (25,737) (25,737) (15,362) (12,381) (1,753,969) (59,585) (28,066) Balance at December 31, 2015 $ 4,750,687 $ - $ 2,985,512 $ 3,545 $ - $ 1,753,969 $ 7,661 $ - Value per Warrant $ 0.202 $ - $ 0.232 $ 0.054 $ - $ 0.170 $ 0.027 $ - December 31, 2015 December 31, 2014 Volatility 162 % 173 % Risk-free interest rate 1.38 % 1.65 %

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2015
Stockholders Equity Note [Abstract]
STOCKHOLDERS' EQUITY	10. STOCKHOLDERS’ EQUITY Common Stock As of December 31, 2015, the Company had 20,408,616 35,018,338 On October 29, 2013, the Company entered into a Securities Purchase Agreement (the “2013 Purchase Agreement”) with certain purchasers identified therein (the “Purchasers”) pursuant to which the Company sold and the Purchasers purchased, an aggregate of 12,868,585 (i) either (a) one share of common stock (each a “Share,” and collectively, the “Shares”), or (b) a five-year common stock warrant to purchase one share of common stock (collectively, the “Series C Warrant Shares”) at an exercise price of $ 0.01 (ii) a five-year warrant to purchase one share of common stock (collectively, the “Series D Warrant Shares”) at an exercise price of $ 4.00 (iii) a warrant, expiring on October 31, 2014, to purchase one share of common stock (collectively, the “Series E Warrant Shares,” and together with the Series C Warrant Shares and the Series D Warrant Shares, the “Warrant Shares”) at an exercise price of $ 2.40 The Company sold and issued 8,413,354 2.40 4,455,231 2.39 30.84 760,000 12,826,752 41,833 The Purchase Agreement contains customary representations, warranties and covenants by each of the Company and the Purchasers. In addition, the Purchase Agreement provides that each Purchaser has a right, subject to certain exceptions described in the agreement, to participate in future issuances of equity and debt securities by the Company for a period of 18 Contemporaneously with the entry into the Purchase Agreement, and as contemplated thereby, the Company entered into a Registration Rights Agreement with the Purchasers. Pursuant to the terms of the Registration Rights Agreement, the Company agreed to file, on or before December 30, 2013 (the “Filing Date”), a registration statement under the Securities Act covering the resale of the Shares and Warrant Shares (the “Registration Statement”), and to cause such Registration Statement to be declared effective by the Commission as soon as practicable thereafter, but not later than 120 days following the date of the Registration Rights Agreement (the “Effectiveness Date”). The Registration Statement was declared effective on January 27, 2014. The Company is required to maintain the effectiveness of the Registration Statement until all of the shares covered thereby are sold or may be sold pursuant to Rule 144 under the Securities Act without volume or manner of- sale restrictions and without the requirement that the Company be in compliance with the current public information requirements of Rule 144. Warrants In accordance with the 2010 sale and issuance of Series A preferred stock, the Company issued two-and-one-half-year “Class A” warrants to purchase an aggregate of 152,740 8.00 801,885 9.20 3.55 0.0 152,740 801,885 Pursuant to the 2012 Purchase Agreement, the Company issued five-year Series A warrants to purchase an aggregate of approximately 6,190,500 4.00 6,190,500 2.40 12 1.8 3.5 6,190,500 In connection with the 2012 offering of the Debentures and 2012 Warrants, the Company engaged Maxim Group LLC, or Maxim Group, to serve as placement agent. In consideration for its services, the Company paid Maxim Group a placement fee of $ 1,035,000 7,500 283,750 2.64 0.0 0.1 Under the terms of the 2013 Purchase Agreement, each Purchaser had the option to elect to receive a Series C Warrant in lieu of a Share in connection with each Unit it purchased. The Series C Warrants have a five-year term and are exercisable at an initial exercise price of $ 0.01 4.00 2.40 3.0 12,868,585 The 2013 Warrants are required to be exercised for cash, provided that if during the term of the warrants there is not an effective registration statement under the Securities Act covering the resale of the shares issuable upon exercise of the warrants, then the warrants may be exercised on a cashless (net exercise) basis. Weighted Average Warrants Exercise Exercise Expiration Warrants Grant Date Issued Price Price Date Exercised Outstanding 11/26/2012 8,822,887 $ 2.40 $ 2.40 11/26/2017 - 8,822,887 11/26/2012 261,250 $ 2.64 $ 2.64 11/26/2017 - 261,250 12/18/2012 1,494,577 $ 2.40 $ 2.40 12/18/2017 - 1,494,577 12/18/2012 22,500 $ 2.64 $ 2.64 12/18/2017 - 22,500 10/29/2013 4,455,231 $ 0.01 $ 0.01 10/29/2018 - 4,455,231 10/29/2013 12,868,585 $ 4.00 $ 4.00 10/29/2018 - 12,868,585 10/29/2013 65,650 $ 2.64 $ 2.64 10/29/2018 - 65,650 27,990,680 $ 2.76 - 27,990,680

STOCK OPTION PLAN

STOCK OPTION PLAN	12 Months Ended
	Dec. 31, 2015
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]
STOCK OPTION PLAN	11. STOCK OPTION PLAN The Company’s 2005 Stock Option Plan (the “Plan”) was originally adopted by the Board of Directors of Old Arno in August 2005, and was assumed by the Company on June 3, 2008 in connection with the Merger. After giving effect to the Merger, there were initially 373,831 875,000 945,276 Company’s of Directors authorized for issuance thereunder 945,276 11,155,295 The Plan is administered by the Board, or a committee appointed by the Board, which determines recipients and types of awards to be granted, including the number of shares subject to the awards, the exercise price and the vesting schedule. The term of stock options granted under the Plan cannot exceed 10 As of December 31, 2015, there are 4,087,657 Year Ended December 31, 2015 2014 Options granted 73,399 2,423,742 Year Ended December 31, 2015 2014 Expected volatility 82% 86% - 92% Expected term 6 years 6 years Dividend yield 0.0% 0.0% Risk- free interest rate 1.64% 1.57% - 1.63% Stock price $0.36 - $0.37 $0.85 - $2.90 Forfeiture rate 0.0% 0.0% Weighted- Aggregate Number of Average Intrinsic Shares Exercise Price Value Options outstanding at December 31, 2014 7,339,118 $ 2.59 $ - Granted 73,399 - - Exercised - - - Cancelled (384,859) $ 2.51 - Options outstanding at December 31, 2015 7,027,658 $ 2.57 $ - Options vested and expected to vest at December 31, 2015 7,027,658 $ 2.57 $ - Exercisable at December 31, 2015 4,975,174 $ 2.67 $ - Shares available for grant under the 2005 Plan 4,087,657 Outstanding Exercisable Weighted- Average Weighted- Remaining Average Weighted- Number of Contractual Exercise Number of Average Exercise Price Shares Life (Years) Price Shares Exercise Price $ 0.36 48,399 9.84 $ 0.36 1,344 $ 0.36 $ 0.37 25,000 9.84 $ 0.37 - $ 0.37 $ 0.85 136,785 8.84 $ 0.85 49,394 $ 0.85 $ 1.30 100,000 8.77 $ 1.30 31,250 $ 1.30 $ 2.23 97,757 0.25 $ 2.23 97,757 $ 2.23 $ 2.40 5,097,075 7.21 $ 2.40 3,752,444 $ 2.40 $ 2.90 1,420,259 8.07 $ 2.90 940,602 $ 2.90 $ 8.00 65,000 4.57 $ 8.00 65,000 $ 8.00 $ 19.38 37,383 2.28 $ 19.38 37,383 $ 19.38 Total 7,027,658 7.32 $ 2.57 4,975,174 $ 2.67 Year Ended December 31, 2015 2014 Research and development $ 804,739 $ 979,792 General and administrative 2,668,021 3,543,876 Total $ 3,472,760 $ 4,523,668 The fair value of options vested under the Plan was approximately $ 4,373,033 3,828,561 At December 31, 2015, total unrecognized estimated compensation cost related to stock options granted prior to that date was approximately $ 3,588,276 2.9 Common stock, stock options or other equity instruments issued to non-employees (including consultants and all members of the Company’s Scientific Advisory Board) as consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued (unless the fair value of the consideration received can be more reliably measured). The fair value of stock options is determined using the Black-Scholes option-pricing model and is expensed as the underlying options vest. The fair value of any options issued to non-employees is recorded as expense over the applicable service periods.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
INCOME TAXES	12. INCOME TAXES The Company accounts for income taxes using the liability method, which requires the determination of deferred tax assets and liabilities, based on the differences between the financial statement and tax bases of assets and liabilities, using enacted tax rates in effect for the year in which differences are expected to reverse. The net deferred tax asset is adjusted by a valuation allowance, if, based on the weight of available evidence, it is more likely than not that some portion or all of the net deferred tax asset will not be realized. The income tax returns of the Company are subject to examination by federal and state taxing authorities. Such examination could result in adjustments to net income or loss, which changes could affect the income tax liabilities of the Company. The Company’s tax returns are open for inspection for all tax years from 2009 to present. The Company’s policy is to include interest and penalties related to unrecognized tax benefits within the Company’s provision for (benefit from) income taxes. The Company recognized no amounts for interest and penalties related to unrecognized tax benefits in 2015 and 2014 and, as of December 31, 2015 and 2014, had no amounts accrued for interest and penalties. At December 31, 2015, the Company had no Federal income tax expense or benefit but did have Federal tax net operating loss carry-forwards of approximately $ 83.9 2026 For Years Ended December 31, 2015 2014 Non-current deferred tax assets: Net operating loss carry forwards $ 33,413,500 $ 30,133,600 Research tax credit 3,459,600 3,267,000 Accrued Expenses 80,000 267,000 Stock based compensation 4,194,500 2,451,000 Total deferred tax assets 41,147,600 36,118,600 Non-current deferred tax liability: Bonus Section 401 adjustment (30,400) (61,000) Depreciation and amortization - - Total net deferred tax assets 41,117,200 36,057,600 Valuation allowance (41,117,200) (36,057,600) Net deferred tax assets $ - $ - The Company records a valuation allowance for temporary differences for which it is more likely than not that the Company will not receive future tax benefits. At December 31, 2015 and 2014 the Company recorded valuation allowances of $ 41.1 36.1 5.0 2015 2014 Amount Rate Amount Rate Federal tax $ (3,912,707) 34.0 % $ 2,642,000 34.0 % State tax (749,087) 6.5 % 511,000 6.6 % Interest expense (653,085) 5.7 % (11,847,000) (152.5) % R&D credit (330,928) 2.9 % (527,000) (6.8) % Other Adjustments 586,206 (5.1) % (1,133,000) (14.6) % Valuation allowance 5,059,601 (44.0) % 10,354,000 133.3 % Net $ - - $ - - There was no income tax benefit recorded for the years ended December 31, 2015 and 2014.

LEASES, COMMITMENTS AND CONTING

LEASES, COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
LEASES, COMMITMENTS AND CONTINGENCIES	13. LEASES, COMMITMENTS AND CONTINGENCIES On August 4, 2011, the Company entered into a lease for office space of approximately 4,168 10,455 January 31, 2018 136,501 90,571 84,833 Future minimum lease payments under operating leases as of December 31, 2015 are as follows: 2016 64,430 2017 66,514 2018 5,557 Total future minimum lease payments $ 136,501 On November 19, 2014, the Company entered into a lease for office equipment. The lease commencement date was November 25, 2014, with lease payments beginning in December 2014. The lease has an initial term of three years and cannot be cancelled or terminated prior to the end of the initial lease term. After the end of the initial term the company can either enter into a new lease, purchase the equipment or return the equipment. Future minimum lease payments under capital leases together with the present value of the net minimum lease payments as of December 31, 2015 are as follows; 2016 4,778 2017 4,380 Total net future minimum lease payments 9,158 Less: Amount representing interest (1,235) Present value of net minimum lease payments $ 7,923 On October 29, 2013, in connection with the entry into the 2013 Purchase Agreement, the Company entered into an agreement (the “OPKO Agreement”) with OPKO Health, Inc. (“OPKO”) and Frost Group, LLC (“Frost Group”). Under the terms of the OPKO Agreement, as in inducement to the participation by OPKO and Frost Group (or its affiliates and associates) in the purchase and sale of the Units under the Purchase Agreement, the Company granted OPKO with the following rights, so long as OPKO continues to hold at least 3% of the total number of outstanding shares of the Company’s common stock, determined on a fully-diluted basis (i.e., assuming the issuance of all shares underlying outstanding options, warrants and other rights to acquire common stock): (1) OPKO shall have the right to appoint a non-voting observer to attend all meetings of the Company’s Board of Directors, provided that such appointee enters into a confidentiality agreement with the Company and shall be subject to all applicable Company policies; and (2) OPKO shall have a right of first negotiation that provides it with exclusive rights to negotiate with the company for a 45-day period regarding any potential strategic transactions that the Company’s Board of Directors elects to pursue. The Company has entered into various contracts with third parties in connection with the development of the licensed technology described in Note 6. The aggregate minimum commitment under these contracts as of December 31, 2015 is approximately $ 6.5 In the normal course of business, the Company enters into contracts that contain a variety of indemnifications with its employees, licensors, suppliers and service providers. Further, the Company indemnifies its directors and officers who are, or were, serving at the Company’s request in such capacities. The Company’s maximum exposure under these arrangements is unknown as of December 31, 2015. The Company does not anticipate recognizing any significant losses relating to these arrangements.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2015
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	14. SUBSEQUENT EVENTS On January 12, 2016, the Company entered into a Stock Purchase Agreement (the “Purchase Agreement”) with certain purchasers identified therein (the “Purchasers”) pursuant to which the Company agreed to sell, and the Purchasers agreed to purchase, an aggregate of 21,153,997 0.35 7.4 2.1 The number of Shares sold pursuant to the Purchase Agreement included an aggregate of 6,081,858 2.1 28,652 The Purchasers included several officers and directors of the Company, or entities affiliated with officers and directors of the Company All such officers and directors made such investment on the same terms as all other Purchasers under the Purchase Agreement. In connection with the entry into the Purchase Agreement, and as contemplated thereby, on January 12, 2016, the Company entered into a Registration Rights Agreement with the Purchasers. Pursuant to the terms of the Registration Rights Agreement, the Company agreed to file, on or before March 12, 2016 (the “Filing Date”), a registration statement under the Securities Act covering the resale of the Shares (the “Registration Statement”), and to cause such Registration Statement to be declared effective by the Commission as soon as practicable thereafter, but not later than 120 days following the date of the Registration Rights Agreement (the “Effectiveness Date”). If the Company does not file the Registration Statement by the Filing Date or obtain its effectiveness by the Effectiveness Date, then the Company is required to pay liquidated damages to the Purchasers in an amount equal to 1 10 On March 14, 2016, the Board of the Company adopted the Company’s 2016 Equity Incentive Plan (the “2016 Plan”). The 2016 Plan replaces the Company’s 2005 Stock Option Plan, which will expire March 31, 2016, and no further awards will be made pursuant to such plan. The Board will initially be the administrator of the 2016 Plan, but the Board may delegate the administration of the 2016 Plan to the Company’s Compensation Committee. The Board and any Committee to which it may delegate the administration of the 2016 Plan are collectively referred to in the 2016 Plan as the “Administrator.” Any employee, director, or consultant may participate in the 2016 Plan; provided, however, that only employees are eligible to receive incentive stock options. Additionally, the Company may grant certain performance-based awards to “covered employees” in compliance with Section 162(m) of the Internal Revenue Code. These covered employees include our executive officers. The stock to be awarded or optioned under the 2016 Plan will consist of authorized but unissued or reacquired shares of common stock. The maximum aggregate number of shares of common stock reserved and available for awards under the 2016 Plan is 9,000,000 2,000,000 The Administrator will adjust the number of shares and share limit described above in the case of a stock dividend, recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-off, repurchase or exchange of shares, or other similar corporate transaction where such an adjustment is necessary to prevent dilution or enlargement of the benefits available under the 2016 Plan. Any adjustment determination made by the Administrator will be final, binding and conclusive. The Administrator may grant awards pursuant to the 2016 Plan until it is discontinued or terminated; provided, however, that incentive stock options may not be granted after March 13, 2026.

SUMMARY OF SIGNIFICANT ACCOUN21

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Use of Estimates	(a) Use of Estimates The preparation of financial statements in conformity with GAAP requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Estimates and assumptions principally relate to services performed by third parties but not yet invoiced, estimates of the fair value and forfeiture rates of stock options issued to employees, directors and consultants, valuation of derivatives and estimates of the probability and potential magnitude of contingent liabilities. Actual results could differ from those estimates.
Cash and cash equivalents	(b) Cash and Cash Equivalents The Company considers all highly liquid investments with a remaining maturity of three months or less at the time of acquisition to be cash equivalents.
Convertible Notes Financing Fees	Finance costs relating to the convertible notes issued are recorded as a direct reduction of the liability and amortized to interest expense over the expected term using the effective interest method.
Prepaid Expenses	(d) Prepaid Expenses Prepaid expenses consist of payments made in advance to vendors relating to service contracts for clinical trial development, insurance policies and license fees. These advanced payments are amortized to expense either as services are performed or over the relevant service period using the straight line method.
Property and Equipment	(e) Property and Equipment Property and equipment consist primarily of furnishings, fixtures, leasehold improvements and computer equipment and are recorded at cost. Repairs and maintenance costs are expensed in the period incurred. Depreciation of property and equipment is provided for by the straight-line method over the estimated useful lives of the related assets. Leasehold improvements are amortized using the straight-line method over the remaining lease term or the life of the asset, whichever is shorter. Description Estimated Useful Life Office equipment and furniture 5 to 7 years Leasehold improvements 3 years Computer equipment 3 years Equipment under capitalized lease Over life of lease
Fair Value of Financial Instruments	(f) Fair Value of Financial Instruments The Company measures fair value in accordance with generally accepted accounting principles. Fair value measurements are applied under other accounting pronouncements that require or permit fair value measurements. Financial instruments included in the Company’s balance sheets consist of cash and cash equivalents, accounts payable, accrued expenses, due to related parties, and derivative liability. The carrying amounts of these instruments reasonably approximate their fair values due to their short-term maturities.
Convertible Debentures and Warrant Liability	(g) Convertible Debentures and Warrant Liability The Company accounts for the convertible debentures and warrants issued in connection with the 2013 Purchase Agreement, the 2012 Purchase Agreement and the 2010 Purchase Agreement (see Note 10) in accordance with the guidance on Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, which provides that the Company classify the warrant instrument as a liability at its fair value and adjusts the instrument to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized as a component of other income or expense. The fair value of warrants issued by the Company, in connection with private placements of securities, has been estimated using a Monte Carlo simulation model and, in doing so, the Company’s management utilized a third-party valuation report. The Monte Carlo simulation is a generally accepted statistical method used to generate a defined number of stock price paths in order to develop a reasonable estimate of the range of the Company’s future expected stock prices and minimizes standard error.
Concentration of Credit Risk	(h) Concentration of Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company deposits cash and cash equivalents with high credit quality financial institutions and is insured to the maximum limitations. Balances in these accounts may exceed federally insured limits at times, which expose the Company to institutional risk.
Research and Development	(i) Research and Development Research and development costs are charged to expense as incurred. Research and development includes employee costs, fees associated with operational consultants, contract clinical research organizations, contract manufacturing organizations, clinical site fees, contract laboratory research organizations, contract central testing laboratories, licensing activities, and allocated executive, human resources and facilities expenses. The Company accrues for costs incurred as the services are being provided by monitoring the status of the trial and the invoices received from its external service providers. As actual costs become known, the Company adjusts its accruals in the period when actual costs become known. Costs related to the acquisition of technology rights and patents for which development work is still in process are charged to operations as incurred and considered a component of research and development expense.
Stock-based compensation	(j) Stock-Based Compensation Stock-based compensation cost is measured at the grant date based on the value of the award and is recognized as expense over the required service period, which is generally equal to the vesting period. Share-based compensation is recognized only for those awards that are ultimately expected to vest. Common stock, stock options or other equity instruments issued to non-employees (including consultants and all members of the Company’s Scientific Advisory Board) as consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued (unless the fair value of the consideration received can be more reliably measured). The fair value of stock options is determined using the Black-Scholes option-pricing model. The fair value of any options issued to non-employees is recorded as expense over the applicable service periods.
Basic and Diluted Income/(Loss) per Common Share	(k) Basic and Diluted Income/(Loss) per Common Share Basic net income/(loss) per share is calculated based on the weighted-average number of shares of common stock outstanding during the period. Diluted net income per share is calculated based on the weighted-average number of shares of common stock and other dilutive securities outstanding during the period. The potential dilutive shares of common stock resulting from the assumed exercise of stock options and warrants are determined under the treasury stock method. Year Ended December 31, 2015 2014 Numerator: Net income/(loss) $ (11,507,963) $ 7,770,767 Denominator: Weighted-average shares of common stock outstanding used in the calculation of basic net income/(loss) per share 20,408,616 20,381,554 Effect of dilutive securities: Warrants to purchase common stock - 4,428,441 Weighted-average shares of common stock outstanding used in the calculation of diluted net income/(loss) per share 20,408,616 24,809,995 For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted loss per share as their effect is anti-dilutive. Year Ended December 31, 2015 2014 Warrants to purchase common stock 4,455,231 4,455,231 For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted net income/(loss) per share if their effect is anti-dilutive. In addition to the potentially dilutive securities, the aggregate number of common equivalent shares (related to options, warrants and convertible debentures) that have been excluded from the computations of diluted net income/(loss) per common share at December 31, 2015 and 2014 were 30,563,107 50,867,639
Comprehensive Loss	(l) Comprehensive Loss The Company has no components of other comprehensive loss other than its net loss, and accordingly, comprehensive loss is equal to net loss for all periods presented.
Income Taxes	(m) Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the period in which the differences are expected to affect taxable income. The Company provides a valuation allowance when it appears more likely than not that some or all of the net deferred tax assets will not be realized. The Company has not performed an Internal Revenue Section 382 limitation study. Depending on the outcome of such study, the gross amount of net operating losses recognized in future tax periods could be limited. A tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The Company’s policy is to include interest and penalties related to unrecognized tax benefits within the Company’s provision for (benefit from) income taxes. The Company recognized no amounts for interest and penalties related to unrecognized tax benefits in 2015 and 2014 respectively. In addition, the Company had no amounts accrued for interest and penalties as of December 31, 2015 and 2014, respectively.
Recently Issued Accounting Pronouncements	In August 2014, the FASB issued Accounting Standards Update No. 2014-15, “Presentation of Financial Statements- Going Concern (Topic 205-40)” (“ASU 2014-15”). Under the standard, management is required to evaluate for each annual and interim reporting period whether it is a probable that the entity will not be able to meet its obligations as they become due within one year after the date that financial statements are issued, or are available to be issued, where applicable. ASU 2014-15 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016, and early adoption is permitted. Accordingly, the standard is effective for the Company on January 1, 2017. The Company will be evaluating the impact, if any, that the standard will have on its financial condition, results of operations, and disclosures in the near future. In April 2015, the FASB issued Accounting Standards Update No. 2015-03, “Interest- Imputation of Interest (Subtopic 835-30)” (“ASU 2015-03”). This standard requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. ASU 2015-03 is effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those years. Accordingly, the standard is effective for the Company on December 15, 2015. The Company adopted ASU 2015-03 as for the fiscal year 2015 and has reported financing costs as a direct reduction from the carrying amount of convertible notes. The Company’s addition of the standard did not have a material impact on its financial condition, results of operations and disclosures. In November 2015, the FASB issued Accounting Standards Update No. 2015-17, “Balance Sheet Classification of Deferred Taxes” (“ASU 2015-17”). The new standard requires all companies to prospectively classify all deferred tax assets and liabilities as noncurrent on the balance sheet. ASU 2015-17 will be effective for public entities on January 1, 2017. However, early adoption is permitted. The Company is evaluating the potential impact of adopting this standard on its financial statements. In January 2016, the FASB issued Accounting Standards Update No. 2016-01, “Financial Instruments” (“ASU 2016-01”). Equity investments not accounted for under the equity method of accounting will be measured at fair value, with changes in fair value recognized in current earnings. ASU 2016-01 becomes effective for fiscal years beginning after December 15, 2017. Early adoption is permitted provided that the guidance is applied from the beginning of the fiscal year of adoption. The Company does not believe the adoption of this standard will have a material impact on its financial statements, results of operations or related financial statement disclosures. In February 2016, the FASB issued Accounting Standards Update No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). Leasees will need to recognize virtually all of their leases on the balance sheet, by recording a right-of-use asset and lease liability. ASU 2016-02 becomes effective for the Company on January 1, 2019, and early adoption is permitted upon issuance.

SUMMARY OF SIGNIFICANT ACCOUN22

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Estimated Useful Life Of Property and Equipment	Description Estimated Useful Life Office equipment and furniture 5 to 7 years Leasehold improvements 3 years Computer equipment 3 years Equipment under capitalized lease Over life of lease
Basic and diluted net income/(loss) per share	Year Ended December 31, 2015 2014 Numerator: Net income/(loss) $ (11,507,963) $ 7,770,767 Denominator: Weighted-average shares of common stock outstanding used in the calculation of basic net income/(loss) per share 20,408,616 20,381,554 Effect of dilutive securities: Warrants to purchase common stock - 4,428,441 Weighted-average shares of common stock outstanding used in the calculation of diluted net income/(loss) per share 20,408,616 24,809,995
Potentially Dilutive Securities	As of December 31, 2015 and 2014, potentially dilutive securities include: Year Ended December 31, 2015 2014 Warrants to purchase common stock 4,455,231 4,455,231

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and equipment as of December 31, 2015 and 2014 consist of the following: 2015 2014 Computer equipment and software $ 17,721 $ 17,721 Office furniture and equipment 72,338 72,338 Leasehold improvements 8,449 8,449 Capital leases- equipment 11,500 11,500 Total property and equipment 110,008 110,008 Accumulated depreciation (86,905) (79,278) Total property and equipment, net $ 23,103 $ 30,730

ACCRUED LIABILITIES (Tables)

ACCRUED LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2015
Payables and Accruals [Abstract]
Schedule Of Accrued Liabilities	Accrued liabilities as of December 31, 2015 and 2014 consist of the following: 2015 2014 Accrued research and development expenses $ 902,723 $ 744,240 Accrued compensation and related benefits 197,457 407,497 Accrued severance - 250,605 Accrued interest on convertible notes 24,510 - Accrued other expenses - 7,951 $ 1,124,690 $ 1,410,293

CONVERTIBLE NOTES PAYABLE (Tabl

CONVERTIBLE NOTES PAYABLE (Tables)	12 Months Ended
	Dec. 31, 2015
Convertible Notes Payable [Abstract]
Unamortized Financing Costs and Net Carrying Amount	The principal balance, unamortized financing costs and net carrying amount of the 6% Note was as follows at December 31, 2015: Unamortized Debt Net Carrying Principal Issuance Costs Amount 6% convertible notes, due October 21, 2016 $ 2,100,000 $ 10,091 $ 2,089,909

FAIR VALUE OF FINANCIAL INSTR26

FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Hierarchy for Liabilities Measured at Fair Value on Recurring Basis	The following table presents the Company’s fair value hierarchy for these assets measured at fair value on a recurring basis as of December 31, 2015: Quoted Market Prices in Active Significant Other Significant Other Fair Value Markets Observable Inputs Unobservable Inputs December 31, 2015 (Level 1) (Level 2) (Level 3) Liabilities: Warrant liability - 2012 Series A $ 1,753,969 $ - $ - $ 1,753,969 Warrant liability - 2012 placement agent 7,661 - - 7,661 Warrant liability - 2013 Series D 2,985,512 - - 2,985,512 Warrant liability - 2013 placement agent 3,545 - - 3,545 Total $ 4,750,687 $ - $ - $ 4,750,687 The following table presents the Company’s fair value hierarchy for these assets measured at fair value on a recurring basis as of December 31, 2014: Quoted Market Prices in Active Significant Other Significant Other Fair Value Markets Observable Inputs Unobservable Inputs December 31, 2014 (Level 1) (Level 2) (Level 3) Liabilities: Warrant liability - 2010 Class B $ 28,066 $ - $ - $ 28,066 Warrant liability - 2012 Series A&B 3,520,319 - - 3,520,319 Warrant liability - 2012 placement agent 67,246 - - 67,246 Warrant liability - 2013 Series D&E 3,036,986 - - 3,036,986 Warrant liability - 2013 placement agent 18,907 - - 18,907 Total $ 6,671,524 $ - $ - $ 6,671,524
Summary of Changes in Fair Value of Liabilities	The following table provides a summary of changes in fair value of the Company’s liabilities, as well as the portion of losses included in income attributable to unrealized depreciation that relate to those liabilities held at December 31, 2015: Fair Value Measurement Using Significant Unobservable Inputs (Level 3) Total 2013 2012 Warrant 2013 2013 Placement 2012 2012 Placement 2010 Liability Series E Series D Agent Series B Series A Agent Class B Balance at January 1, 2014 $ 35,864,881 $ 5,855,206 $ 12,482,527 $ 98,080 $ 2,816,676 $ 13,887,307 $ 362,633 $ 362,452 Total gains or losses: Unrealized appreciation (29,193,357) (5,829,469) (9,471,278) (79,173) (2,804,295) (10,379,369) (295,387) (334,386) Balance at December 31, 2014 $ 6,671,524 $ 25,737 $ 3,011,249 $ 18,907 $ 12,381 $ 3,507,938 $ 67,246 $ 28,066 Total gains or losses: Unrealized appreciation (1,920,837) (25,737) (25,737) (15,362) (12,381) (1,753,969) (59,585) (28,066) Balance at December 31, 2015 $ 4,750,687 $ - $ 2,985,512 $ 3,545 $ - $ 1,753,969 $ 7,661 $ - Value per Warrant $ 0.202 $ - $ 0.232 $ 0.054 $ - $ 0.170 $ 0.027 $ -
Schedule of Derivative Liabilities at Fair Value	Significant assumptions used at December 31, 2015 and 2014 for the warrants and embedded conversion discount derivative liability of the Debentures are as follows: December 31, 2015 December 31, 2014 Volatility 162 % 173 % Risk-free interest rate 1.38 % 1.65 %

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	12 Months Ended
	Dec. 31, 2015
Stockholders Equity Note [Abstract]
Summary of All Outstanding Warrants to Purchase Shares of Common Stock	Below is a table that summarizes all outstanding warrants to purchase shares of the Company’s common stock as of December 31, 2015. Weighted Average Warrants Exercise Exercise Expiration Warrants Grant Date Issued Price Price Date Exercised Outstanding 11/26/2012 8,822,887 $ 2.40 $ 2.40 11/26/2017 - 8,822,887 11/26/2012 261,250 $ 2.64 $ 2.64 11/26/2017 - 261,250 12/18/2012 1,494,577 $ 2.40 $ 2.40 12/18/2017 - 1,494,577 12/18/2012 22,500 $ 2.64 $ 2.64 12/18/2017 - 22,500 10/29/2013 4,455,231 $ 0.01 $ 0.01 10/29/2018 - 4,455,231 10/29/2013 12,868,585 $ 4.00 $ 4.00 10/29/2018 - 12,868,585 10/29/2013 65,650 $ 2.64 $ 2.64 10/29/2018 - 65,650 27,990,680 $ 2.76 - 27,990,680

STOCK OPTION PLAN (Tables)

STOCK OPTION PLAN (Tables)	12 Months Ended
	Dec. 31, 2015
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]
Schedule of Share-based Compensation, Activity	During the years ended December 31, 2015 and December 31, 2014 the Company issued the following stock options: Year Ended December 31, 2015 2014 Options granted 73,399 2,423,742
Assumptions Used in Estimating Fair Value of Each Option Award Granted Using Black-Scholes Option-Pricing Model	The Company estimated the fair value of each option award granted using the Black-Scholes option-pricing model. The following assumptions were used for the years ended December 31, 2015 and 2014: Year Ended December 31, 2015 2014 Expected volatility 82% 86% - 92% Expected term 6 years 6 years Dividend yield 0.0% 0.0% Risk- free interest rate 1.64% 1.57% - 1.63% Stock price $0.36 - $0.37 $0.85 - $2.90 Forfeiture rate 0.0% 0.0%
Summary of Status of Options Issued And Changes in Options Outstanding	A summary of the status of the options issued under the Plan at December 31, 2015, and information with respect to the changes in options outstanding is as follows: Weighted- Aggregate Number of Average Intrinsic Shares Exercise Price Value Options outstanding at December 31, 2014 7,339,118 $ 2.59 $ - Granted 73,399 - - Exercised - - - Cancelled (384,859) $ 2.51 - Options outstanding at December 31, 2015 7,027,658 $ 2.57 $ - Options vested and expected to vest at December 31, 2015 7,027,658 $ 2.57 $ - Exercisable at December 31, 2015 4,975,174 $ 2.67 $ - Shares available for grant under the 2005 Plan 4,087,657
Summary of Stock Options Outstanding	The following table summarizes information about stock options outstanding at December 31, 2015: Outstanding Exercisable Weighted- Average Weighted- Remaining Average Weighted- Number of Contractual Exercise Number of Average Exercise Price Shares Life (Years) Price Shares Exercise Price $ 0.36 48,399 9.84 $ 0.36 1,344 $ 0.36 $ 0.37 25,000 9.84 $ 0.37 - $ 0.37 $ 0.85 136,785 8.84 $ 0.85 49,394 $ 0.85 $ 1.30 100,000 8.77 $ 1.30 31,250 $ 1.30 $ 2.23 97,757 0.25 $ 2.23 97,757 $ 2.23 $ 2.40 5,097,075 7.21 $ 2.40 3,752,444 $ 2.40 $ 2.90 1,420,259 8.07 $ 2.90 940,602 $ 2.90 $ 8.00 65,000 4.57 $ 8.00 65,000 $ 8.00 $ 19.38 37,383 2.28 $ 19.38 37,383 $ 19.38 Total 7,027,658 7.32 $ 2.57 4,975,174 $ 2.67
Stock-Based Compensation Costs	Stock-based compensation costs under the Plan for the year ended December 31, 2015 and 2014 are as follows: Year Ended December 31, 2015 2014 Research and development $ 804,739 $ 979,792 General and administrative 2,668,021 3,543,876 Total $ 3,472,760 $ 4,523,668

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Schedule of Deferred Tax Assets and Liabilities	Significant components of the Company’s net deferred tax assets at December 31, 2015 and 2014 are shown below. For Years Ended December 31, 2015 2014 Non-current deferred tax assets: Net operating loss carry forwards $ 33,413,500 $ 30,133,600 Research tax credit 3,459,600 3,267,000 Accrued Expenses 80,000 267,000 Stock based compensation 4,194,500 2,451,000 Total deferred tax assets 41,147,600 36,118,600 Non-current deferred tax liability: Bonus Section 401 adjustment (30,400) (61,000) Depreciation and amortization - - Total net deferred tax assets 41,117,200 36,057,600 Valuation allowance (41,117,200) (36,057,600) Net deferred tax assets $ - $ -
Schedule of Effective Income Tax Rate Reconciliation	A reconciliation of the statutory tax rates and the effective tax rates for the years ended December 31, 2015 and 2014 are as follows: 2015 2014 Amount Rate Amount Rate Federal tax $ (3,912,707) 34.0 % $ 2,642,000 34.0 % State tax (749,087) 6.5 % 511,000 6.6 % Interest expense (653,085) 5.7 % (11,847,000) (152.5) % R&D credit (330,928) 2.9 % (527,000) (6.8) % Other Adjustments 586,206 (5.1) % (1,133,000) (14.6) % Valuation allowance 5,059,601 (44.0) % 10,354,000 133.3 % Net $ - - $ - -

LEASES, COMMITMENTS AND CONTI30

LEASES, COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Future minimum lease payments under operating leases	Future minimum lease payments under operating leases as of December 31, 2015 2016 64,430 2017 66,514 2018 5,557 Total future minimum lease payments $ 136,501
Future minimum lease payments under capital leases	Future minimum lease payments under capital leases as of December 31, 2015 2016 4,778 2017 4,380 Total net future minimum lease payments 9,158 Less: Amount representing interest (1,235) Present value of net minimum lease payments $ 7,923

Description of Business - Addit

Description of Business - Additional Information (Detail)	Dec. 31, 2015
Organization and Nature of Operations [Line Items]
Percentage of outstanding common stock collectively held by former stockholders of Old Arno	95.00%

Liquidity and Capital Resourc32

Liquidity and Capital Resources - Additional Information (Detail) - USD ($)	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Working Capital Detail [Line Items]
Cash and cash equivalents	$ 66,988	$ 7,948,436	$ 26,774,203

The Merger and Basis of Prese33

The Merger and Basis of Presentation - Additional Information (Detail) - USD ($)	Jun. 03, 2008	Jun. 02, 2008	Dec. 31, 2015	Dec. 31, 2014
Merger and Basis of Presentation [Line Items]
Number of shares issued on conversion of 6% notes		1,962,338
Accumulated deficit	$ 120,538		$ (93,294,953)	$ (81,786,990)
Common Stock
Merger and Basis of Presentation [Line Items]
Number of securities called by warrants		196,189
Per share exercise price of warrant		$ 2.42
Old Arno
Merger and Basis of Presentation [Line Items]
Shares issuable prior to merger ratio	$ 1.99377
Shares issued in merger	1,611,760
Ownership interest	95.00%
Number of shares issued in business combination		7,360,700
Gross proceeds private placement		$ 17,732,000
Sale of Stock		3,691,900
Notes interest rate		6.00%
Number of shares issued on conversion of 6% notes		984,246
Number of securities called by warrants		98,409
Per share exercise price of warrant		$ 4.83
Laurier International Inc
Merger and Basis of Presentation [Line Items]
Shares issued in merger	19,291,824
Common stock outstanding prior to merger	1,100,200

Summary Of Significant Accoun34

Summary Of Significant Accounting Policies - Additional Information (Detail) - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Summary Of Significant Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	30,563,107	50,867,639

Straight - Line Method over Rem

Straight - Line Method over Remaining Lease Term or Life of Asset (Detail)	12 Months Ended
	Dec. 31, 2015
Office equipment and furniture | Maximum
Property Plant And Equipment Estimated Useful Life [Line Items]
Property, Plant and Equipment, Useful Life	7 years
Office equipment and furniture | Minimum
Property Plant And Equipment Estimated Useful Life [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Leasehold improvements
Property Plant And Equipment Estimated Useful Life [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Computer equipment
Property Plant And Equipment Estimated Useful Life [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Equipment under capitalized lease
Property Plant And Equipment Estimated Useful Life [Line Items]
Property, Plant and Equipment, Useful Life Description	Over life of lease

Basic and diluted net income_(l

Basic and diluted net income/(loss) per share (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Numerator:
Net income/(loss)	$ (11,507,963)	$ 7,770,767
Denominator:
Weighted-average shares of common stock outstanding used in the calculation of basic net income/(loss) per share	20,408,616	20,381,554
Effect of dilutive securities:
Warrants to purchase common stock	0	4,428,441
Weighted-average shares of common stock outstanding used in the calculation of diluted net income/(loss) per share	20,408,616	24,809,995

Potentially Dilutive Securities

Potentially Dilutive Securities (Detail) - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Warrants to purchase common stock
Potentially Dilutive Securities Included in Computation of Earnings Per Share [Line Items]
Purchase common stock	4,455,231	4,455,231

Property and Equipment - Additi

Property and Equipment - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Depreciation and amortization	$ 7,627	$ 12,586

Property and Equipment (Detail)

Property and Equipment (Detail) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Computer equipment and software	$ 17,721	$ 17,721
Office furniture and equipment	72,338	72,338
Leasehold improvements	8,449	8,449
Capital leases- equipment	11,500	11,500
Total property and equipment	110,008	110,008
Accumulated depreciation	(86,905)	(79,278)
Total property and equipment, net	$ 23,103	$ 30,730

Intangible Assets and Intelle40

Intangible Assets and Intellectual Property - Additional Information (Detail) - USD ($)	Apr. 01, 2014	Feb. 13, 2012	Jul. 31, 2015	Jan. 31, 2014	Oct. 31, 2013	Dec. 31, 2008
Finite-Lived Intangible Assets [Line Items]
Services agreement monthly payment	$ 50,000	$ 70,833
Onapristone License Agreement
Finite-Lived Intangible Assets [Line Items]
Written notice period for termination of license agreement if breach is not cured		90 days
Onapristone License Agreement | Invivis Pharmaceuticals, Inc
Finite-Lived Intangible Assets [Line Items]
Cash paid under license agreement		$ 500,000		$ 100,000	$ 150,000
Aggregate potential milestone payments		$ 15,100,000
License agreement termination date		Feb. 13, 2032
Prior written notice period for termination of license agreement by the company for any reason		90 days
Onapristone License Agreement | Invivis Pharmaceuticals, Inc | Next Milestone Payment
Finite-Lived Intangible Assets [Line Items]
Cash paid under license agreement			$ 350,000
AR-12 and AR-42 License Agreements | Ohio State University Research Foundation
Finite-Lived Intangible Assets [Line Items]
Cash paid under license agreement						$ 450,000
Written notice period for termination of license agreement if breach is not cured						90 days
Prior written notice period for termination of license agreement by the company for any reason						90 days
License agreement expiration date						20 years
AR-12 License Agreement | Ohio State University Research Foundation
Finite-Lived Intangible Assets [Line Items]
Aggregate potential milestone payments						$ 6,100,000
Potential milestone payments, due after market approval						5,000,000
AR-42 License Agreement | Ohio State University Research Foundation
Finite-Lived Intangible Assets [Line Items]
Aggregate potential milestone payments						5,100,000
Potential milestone payments, due after market approval						$ 4,000,000

Accrued Liabilities (Detail)

Accrued Liabilities (Detail) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Accrued research and development expenses	$ 902,723	$ 744,240
Accrued compensation and related benefits	197,457	407,497
Accrued severance	0	250,605
Accrued interest on convertible notes	24,510	0
Accrued other expenses	0	7,951
Total	$ 1,124,690	$ 1,410,293

Convertible Notes Payable - (Ad

Convertible Notes Payable - (Additional Information) (Detail) - Convertible Notes Payable [Member] - USD ($)	1 Months Ended
	Oct. 21, 2015	Dec. 31, 2015
Convertible Long Term Notes Payable [Line Items]
Potential Additional Equity Financing	$ 3,500,000
Debt Issuance Cost	12,528
Deposit Liabilities, Accrued Interest		$ 24,510
Convertible Note Payable, Face Amount	$ 2,100,000
Debt Instrument, Interest Rate, Stated Percentage	6.00%
Debt Conversion, Converted Instrument, Amount	$ 2,100,000
Debt Instrument, Maturity Date	Oct. 21, 2016

Unamortized Financing Costs and

Unamortized Financing Costs and Net Carrying Amount (Detail)	Dec. 31, 2015USD ($)
Unamortized Debt Issuance Costs	$ 10,091
6% convertible notes, due October 21, 2016
Principal	2,100,000
Unamortized Debt Issuance Costs	10,091
Net Carrying Amount	$ 2,089,909

Fair Value Hierarchy for Liabil

Fair Value Hierarchy for Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Liabilities
Derivative Liabilities Noncurrent	$ 4,750,687	$ 6,671,524
Fair Value, Measurements, Recurring
Liabilities
Derivative Liabilities Noncurrent	4,750,687	6,671,524
Fair Value, Measurements, Recurring | Warrant liability - 2010 Class B
Liabilities
Derivative Liabilities Noncurrent		28,066
Fair Value, Measurements, Recurring | Warrant liability - 2012 Series A
Liabilities
Derivative Liabilities Noncurrent	1,753,969
Fair Value, Measurements, Recurring | Warrant liability - 2012 Series A&B
Liabilities
Derivative Liabilities Noncurrent		3,520,319
Fair Value, Measurements, Recurring | Warrant liability - 2012 placement agent
Liabilities
Derivative Liabilities Noncurrent	7,661	67,246
Fair Value, Measurements, Recurring | Warrant liability - 2013 Series D
Liabilities
Derivative Liabilities Noncurrent	2,985,512
Fair Value, Measurements, Recurring | Warrant liability - 2013 Series D&E
Liabilities
Derivative Liabilities Noncurrent		3,036,986
Fair Value, Measurements, Recurring | Warrant liability - 2013 placement agent
Liabilities
Derivative Liabilities Noncurrent	3,545	18,907
Quoted Market Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring
Liabilities
Derivative Liabilities Noncurrent	0	0
Quoted Market Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Warrant liability - 2010 Class B
Liabilities
Derivative Liabilities Noncurrent		0
Quoted Market Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Warrant liability - 2012 Series A
Liabilities
Derivative Liabilities Noncurrent	0
Quoted Market Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Warrant liability - 2012 Series A&B
Liabilities
Derivative Liabilities Noncurrent		0
Quoted Market Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Warrant liability - 2012 placement agent
Liabilities
Derivative Liabilities Noncurrent	0	0
Quoted Market Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Warrant liability - 2013 Series D
Liabilities
Derivative Liabilities Noncurrent	0
Quoted Market Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Warrant liability - 2013 Series D&E
Liabilities
Derivative Liabilities Noncurrent		0
Quoted Market Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Warrant liability - 2013 placement agent
Liabilities
Derivative Liabilities Noncurrent	0	0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring
Liabilities
Derivative Liabilities Noncurrent	0	0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Warrant liability - 2010 Class B
Liabilities
Derivative Liabilities Noncurrent		0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Warrant liability - 2012 Series A
Liabilities
Derivative Liabilities Noncurrent	0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Warrant liability - 2012 Series A&B
Liabilities
Derivative Liabilities Noncurrent		0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Warrant liability - 2012 placement agent
Liabilities
Derivative Liabilities Noncurrent	0	0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Warrant liability - 2013 Series D
Liabilities
Derivative Liabilities Noncurrent	0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Warrant liability - 2013 Series D&E
Liabilities
Derivative Liabilities Noncurrent		0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Warrant liability - 2013 placement agent
Liabilities
Derivative Liabilities Noncurrent	0	0
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring
Liabilities
Derivative Liabilities Noncurrent	4,750,687	6,671,524
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Warrant liability - 2010 Class B
Liabilities
Derivative Liabilities Noncurrent		28,066
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Warrant liability - 2012 Series A
Liabilities
Derivative Liabilities Noncurrent	1,753,969
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Warrant liability - 2012 Series A&B
Liabilities
Derivative Liabilities Noncurrent		3,520,319
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Warrant liability - 2012 placement agent
Liabilities
Derivative Liabilities Noncurrent	7,661	67,246
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Warrant liability - 2013 Series D
Liabilities
Derivative Liabilities Noncurrent	2,985,512
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Warrant liability - 2013 Series D&E
Liabilities
Derivative Liabilities Noncurrent		3,036,986
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Warrant liability - 2013 placement agent
Liabilities
Derivative Liabilities Noncurrent	$ 3,545	$ 18,907

Summary of Changes in Fair Valu

Summary of Changes in Fair Value of Liabilities (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
2013 Series E
Warrant Liability
Balance	$ 25,737	$ 5,855,206
Total gains or losses:
Unrealized appreciation	(25,737)	(5,829,469)
Balance	$ 0	25,737
Value per Warrant	$ 0
2013 Series D
Warrant Liability
Balance	$ 3,011,249	12,482,527
Total gains or losses:
Unrealized appreciation	(25,737)	(9,471,278)
Balance	$ 2,985,512	3,011,249
Value per Warrant	$ 0.232
2013 Placement Agent
Warrant Liability
Balance	$ 18,907	98,080
Total gains or losses:
Unrealized appreciation	(15,362)	(79,173)
Balance	$ 3,545	18,907
Value per Warrant	$ 0.054
2012 Series B
Warrant Liability
Balance	$ 12,381	2,816,676
Total gains or losses:
Unrealized appreciation	(12,381)	(2,804,295)
Balance	$ 0	12,381
Value per Warrant	$ 0
2012 Series A
Warrant Liability
Balance	$ 3,507,938	13,887,307
Total gains or losses:
Unrealized appreciation	(1,753,969)	(10,379,369)
Balance	$ 1,753,969	3,507,938
Value per Warrant	$ 0.170
2012 Placement Agent
Warrant Liability
Balance	$ 67,246	362,633
Total gains or losses:
Unrealized appreciation	(59,585)	(295,387)
Balance	$ 7,661	67,246
Value per Warrant	$ 0.027
2010 Class B
Warrant Liability
Balance	$ 28,066	362,452
Total gains or losses:
Unrealized appreciation	(28,066)	(334,386)
Balance	$ 0	28,066
Value per Warrant	$ 0
Warrant
Warrant Liability
Balance	$ 6,671,524	35,864,881
Total gains or losses:
Unrealized appreciation	(1,920,837)	(29,193,357)
Balance	$ 4,750,687	$ 6,671,524
Value per Warrant	$ 0.202

Warrants and Embedded Conversio

Warrants and Embedded Conversion Discount Derivative Liability (Detail)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Volatility	162.00%	173.00%
Risk-free interest rate	1.38%	1.65%

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	1 Months Ended				12 Months Ended
	Sep. 30, 2015	Jan. 31, 2015	Oct. 30, 2013	Oct. 29, 2013	Dec. 31, 2015	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2010	Dec. 31, 2014	Oct. 31, 2014
Stockholders Equity Note [Line Items]
Common stock, shares issued					20,408,616				20,408,616
Common stock, shares outstanding					20,408,616				20,408,616
Derivative liabilities					$ 4,750,687				$ 6,671,524
Sale Of Stock Units			41,833	12,826,752
Stock Units Issued Related Cost				$ 760,000
Gross Proceeds From Issuance Of Units				$ 30,840,000
Potential Additional Equity Financing							$ 12,000,000
Future Issuance of Equity and Debt Security Term					18 months
Common Shares
Stockholders Equity Note [Line Items]
Shares Of Common Stock Reserved For Issuance Upon The Exercise Of Outstanding Options And Warrants					35,018,338
Maxim Group Llc
Stockholders Equity Note [Line Items]
Common stock, shares issued							7,500
Number of securities called by warrants							283,750
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 2.64
Warrant Term							5 years
Derivative liabilities					$ 0				100,000
Placement Fee Paid							$ 1,035,000
Class A Warrants
Stockholders Equity Note [Line Items]
Number of securities called by warrants								152,740
Class Of Warrant Or Right Initial Exercise Price Of Warrants Or Rights								$ 8
Number Of Warrants Expired Unexercised						152,740
Class B Warrants
Stockholders Equity Note [Line Items]
Number of securities called by warrants								801,885
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 3.55
Warrant Term								5 years
Derivative liabilities					0				0
Class Of Warrant Or Right Initial Exercise Price Of Warrants Or Rights								$ 9.20
Number Of Warrants Expired Unexercised	801,885
Series A Warrant
Stockholders Equity Note [Line Items]
Number of securities called by warrants							6,190,500
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 4
Warrant Term							5 years
Series B Warrant
Stockholders Equity Note [Line Items]
Number of securities called by warrants							6,190,500
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 2.40
Number Of Warrants Expired Unexercised		6,190,500
Series C Warrant
Stockholders Equity Note [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.01
Warrant Term				5 years		5 years
Series D Warrant
Stockholders Equity Note [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 4		$ 4
Warrant Term				5 years		5 years
Series E Warrant
Stockholders Equity Note [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 2.40
Number Of Warrants Expired Unexercised		12,868,585
Securities Purchase and Registration Rights Agreement | Series C Warrant
Stockholders Equity Note [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 0.01
Securities Purchase and Registration Rights Agreement | Series E Warrant
Stockholders Equity Note [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights										$ 2.40
Common Stock
Stockholders Equity Note [Line Items]
Sale Of Stock Units				12,868,585
Series D Warrants and Series E Warrants
Stockholders Equity Note [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 2.40
Derivative liabilities					3,000,000				3,000,000
Stock Issued During Period, Shares, Conversion of Units				8,413,354
Series C Warrants, Series D Warrants and Series E Warrants
Stockholders Equity Note [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 2.39
Sale Of Stock Units				4,455,231
Series A and B Warrants
Stockholders Equity Note [Line Items]
Derivative liabilities					$ 1,800,000				$ 3,500,000

Summary of All Outstanding Warr

Summary of All Outstanding Warrants to Purchase Shares of Common Stock (Detail)	12 Months Ended
	Dec. 31, 2015$ / shares$ / Warrantshares
Warrant 1
Class of Warrant or Right [Line Items]
Grant Date	Nov. 26, 2012
Warrants Issued	8,822,887
Exercise Price | $ / shares	$ 2.40
Weighted Average Exercise Price | $ / Warrant	2.40
Expiration Date	Nov. 26, 2017
Exercised	0
Warrants Outstanding	8,822,887
Warrant 2
Class of Warrant or Right [Line Items]
Grant Date	Nov. 26, 2012
Warrants Issued	261,250
Exercise Price | $ / shares	$ 2.64
Weighted Average Exercise Price | $ / Warrant	2.64
Expiration Date	Nov. 26, 2017
Exercised	0
Warrants Outstanding	261,250
Warrant 3
Class of Warrant or Right [Line Items]
Grant Date	Dec. 18, 2012
Warrants Issued	1,494,577
Exercise Price | $ / shares	$ 2.40
Weighted Average Exercise Price | $ / Warrant	2.40
Expiration Date	Dec. 18, 2017
Exercised	0
Warrants Outstanding	1,494,577
Warrant 4
Class of Warrant or Right [Line Items]
Grant Date	Dec. 18, 2012
Warrants Issued	22,500
Exercise Price | $ / shares	$ 2.64
Weighted Average Exercise Price | $ / Warrant	2.64
Expiration Date	Dec. 18, 2017
Exercised	0
Warrants Outstanding	22,500
Warrant 5
Class of Warrant or Right [Line Items]
Grant Date	Oct. 29, 2013
Warrants Issued	4,455,231
Exercise Price | $ / shares	$ 0.01
Weighted Average Exercise Price | $ / Warrant	0.01
Expiration Date	Oct. 29, 2018
Exercised	0
Warrants Outstanding	4,455,231
Warrant 6
Class of Warrant or Right [Line Items]
Grant Date	Oct. 29, 2013
Warrants Issued	12,868,585
Exercise Price | $ / shares	$ 4
Weighted Average Exercise Price | $ / Warrant	4
Expiration Date	Oct. 29, 2018
Exercised	0
Warrants Outstanding	12,868,585
Warrant 7
Class of Warrant or Right [Line Items]
Grant Date	Oct. 29, 2013
Warrants Issued	65,650
Exercise Price | $ / shares	$ 2.64
Weighted Average Exercise Price | $ / Warrant	2.64
Expiration Date	Oct. 29, 2018
Exercised	0
Warrants Outstanding	65,650
Total Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants Issued	27,990,680
Weighted Average Exercise Price | $ / Warrant	2.76
Exercised	0
Warrants Outstanding	27,990,680

Stock Option Plan - Additional

Stock Option Plan - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Oct. 07, 2013	Jan. 14, 2013	Apr. 25, 2011	Jun. 03, 2008
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of stock options granted under 2005 Plan (in years)	7 years 3 months 25 days
Fair value of options vested under 2005 Plan	$ 4,373,033	$ 3,828,561
Total unrecognized estimated compensation cost related to stock options	$ 3,588,276
Total unrecognized estimated compensation cost related to stock options, recognition period	2 years 10 months 24 days
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of stock options granted under 2005 Plan (in years)	10 years
Stock Options, Warrants Restricted Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Available For Grant	4,087,657
2005 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock reserved for issuance under 2005 Plan				945,276	875,000	373,831
2005 Plan | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock reserved for issuance under 2005 Plan			11,155,295
2005 Plan | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock reserved for issuance under 2005 Plan			945,276

Options Granted (Detail)

Options Granted (Detail) - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options granted	73,399	2,423,742

Assumptions Used in Estimating

Assumptions Used in Estimating Fair Value of Each Option Award Granted Using Black-Scholes Option-Pricing Model (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected Volatility	82.00%
Expected term	6 years	6 years
Dividend yield	0.00%	0.00%
Risk-free interest rate	1.64%
Forfeiture rate	0.00%	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected Volatility		86.00%
Risk-free interest rate		1.57%
Stock price	$ 0.36	$ 0.85
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected Volatility		92.00%
Risk-free interest rate		1.63%
Stock price	$ 0.37	$ 2.90

Summary of Status of Options Is

Summary of Status of Options Issued and Changes in Options Outstanding (Detail)	12 Months Ended
	Dec. 31, 2015USD ($)$ / sharesshares
Number of Shares
Ending Balance	7,027,658
Exercisable	4,975,174
Weighted-Average Exercise Price
Ending Balance | $ / shares	$ 2.57
Exercisable | $ / shares	$ 2.67
Stock Option Plan
Number of Shares
Beginning Balance	7,339,118
Options Granted	73,399
Options Exercised	0
Options Cancelled	(384,859)
Ending Balance	7,027,658
Options vested and expected to vest	7,027,658
Exercisable	4,975,174
Shares available for grant under the 2005 Plan	4,087,657
Weighted-Average Exercise Price
Beginning Balance | $ / shares	$ 2.59
Options Granted | $ / shares	0
Options Exercised | $ / shares	0
Options Cancelled | $ / shares	2.51
Ending Balance | $ / shares	2.57
Options vested and expected to vest | $ / shares	2.57
Exercisable | $ / shares	$ 2.67
Aggregate Intrinsic Value
Beginning Balance | $	$ 0
Options Granted | $	0
Options Exercised | $	0
Options Cancelled | $	0
Ending Balance | $	0
Options vested and expected | $	0
Exercisable | $	$ 0

Summary of Information about St

Summary of Information about Stock Options Outstanding (Detail)	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Shares | shares	7,027,658
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	7 years 3 months 25 days
Options Outstanding, Weighted-Average Exercise Price | $ / shares	$ 2.57
Options Exercisable, Shares | shares	4,975,174
Options Exercisable, Weighted- Average Exercise Price | $ / shares	$ 2.67
Exercise Price 0.36
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Shares | shares	48,399
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	9 years 10 months 2 days
Options Outstanding, Weighted-Average Exercise Price | $ / shares	$ 0.36
Options Exercisable, Shares | shares	1,344
Options Exercisable, Weighted- Average Exercise Price | $ / shares	$ 0.36
Exercise Price 0.37
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Shares | shares	25,000
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	9 years 10 months 2 days
Options Outstanding, Weighted-Average Exercise Price | $ / shares	$ 0.37
Options Exercisable, Shares | shares	0
Options Exercisable, Weighted- Average Exercise Price | $ / shares	$ 0.37
Exercise Price 0.85
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Shares | shares	136,785
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	8 years 10 months 2 days
Options Outstanding, Weighted-Average Exercise Price | $ / shares	$ 0.85
Options Exercisable, Shares | shares	49,394
Options Exercisable, Weighted- Average Exercise Price | $ / shares	$ 0.85
Exercise Price 1.30
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Shares | shares	100,000
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	8 years 9 months 7 days
Options Outstanding, Weighted-Average Exercise Price | $ / shares	$ 1.30
Options Exercisable, Shares | shares	31,250
Options Exercisable, Weighted- Average Exercise Price | $ / shares	$ 1.30
Exercise Price 2.23
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Shares | shares	97,757
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	3 months
Options Outstanding, Weighted-Average Exercise Price | $ / shares	$ 2.23
Options Exercisable, Shares | shares	97,757
Options Exercisable, Weighted- Average Exercise Price | $ / shares	$ 2.23
Exercise Price 2.40
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Shares | shares	5,097,075
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	7 years 2 months 16 days
Options Outstanding, Weighted-Average Exercise Price | $ / shares	$ 2.40
Options Exercisable, Shares | shares	3,752,444
Options Exercisable, Weighted- Average Exercise Price | $ / shares	$ 2.40
Exercise Price 2.90
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Shares | shares	1,420,259
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	8 years 25 days
Options Outstanding, Weighted-Average Exercise Price | $ / shares	$ 2.90
Options Exercisable, Shares | shares	940,602
Options Exercisable, Weighted- Average Exercise Price | $ / shares	$ 2.90
Exercise price 8.00
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Shares | shares	65,000
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	4 years 6 months 25 days
Options Outstanding, Weighted-Average Exercise Price | $ / shares	$ 8
Options Exercisable, Shares | shares	65,000
Options Exercisable, Weighted- Average Exercise Price | $ / shares	$ 8
Exercise price 19.38
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Shares | shares	37,383
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	2 years 3 months 11 days
Options Outstanding, Weighted-Average Exercise Price | $ / shares	$ 19.38
Options Exercisable, Shares | shares	37,383
Options Exercisable, Weighted- Average Exercise Price | $ / shares	$ 19.38

Stock-Based Compensation Costs

Stock-Based Compensation Costs (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation costs	$ 3,472,760	$ 4,523,668
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation costs	804,739	979,792
General and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation costs	$ 2,668,021	$ 3,543,876

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Line Items]
Deferred Tax Assets, Valuation Allowance	$ 41,117,200	$ 36,057,600
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	5,000,000
Deferred Tax Assets, Operating Loss Carryforwards, Domestic	$ 83,900,000
Operating Loss Carry Forward Expiration Date	2,026

Significant Components of Net D

Significant Components of Net Deferred Tax Assets (Detail) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Non-current deferred tax assets:
Net operating loss carry forwards	$ 33,413,500	$ 30,133,600
Research tax credit	3,459,600	3,267,000
Accrued expenses	80,000	267,000
Stock based compensation	4,194,500	2,451,000
Total deferred tax assets	41,147,600	36,118,600
Non-current deferred tax liability:
Bonus Section 401 adjustment	(30,400)	(61,000)
Depreciation and amortization	0	0
Total net deferred tax assets	41,117,200	36,057,600
Valuation allowance	(41,117,200)	(36,057,600)
Net deferred tax assets	$ 0	$ 0

Reconciliation of Statutory Tax

Reconciliation of Statutory Tax Rates and Effective Tax Rates (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Schedule Of Effective Income Tax Rate Reconciliation [Line Items]
Federal tax	$ (3,912,707)	$ 2,642,000
State tax	(749,087)	511,000
Interest expense	(653,085)	(11,847,000)
R&D credit	(330,928)	(527,000)
Other Adjustments	586,206	(1,133,000)
Valuation allowance	5,059,601	10,354,000
Net	$ 0	$ 0
Federal Tax	34.00%	34.00%
State Tax	6.50%	6.60%
Interest Expense	5.70%	(152.50%)
R&D credit	2.90%	(6.80%)
Other adjustments	(5.10%)	(14.60%)
Valuation allowance	(44.00%)	133.30%
Net	0.00%	0.00%

Leases, Commitments and Conti58

Leases, Commitments and Contingencies - Additional Information (Detail)	1 Months Ended	12 Months Ended
	Jun. 17, 2014	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Aug. 04, 2011ft²
Leases, Commitments And Contingencies Disclosure [Line Items]
Deposits Assets, Noncurrent		$ 10,455	$ 10,455
Purchase Commitment, Remaining Minimum Amount Committed		6,500,000
Lease Expiration Date	Jan. 31, 2018
Operating Leases, Future Minimum Payments Due		$ 136,501
Description of Lessee Leasing Arrangements, Capital Leases		The lease has an initial term of three years and cannot be cancelled or terminated prior to the end of the initial lease term. After the end of the initial term the company can either enter into a new lease, purchase the equipment or return the equipment.
Flemington Lease
Leases, Commitments And Contingencies Disclosure [Line Items]
Operating Leases, Rent Expense		$ 90,571	$ 84,833
Flemington Lease sqft
Leases, Commitments And Contingencies Disclosure [Line Items]
Area of Land | ft²				4,168

Future Minimum Lease Payments U

Future Minimum Lease Payments Under Operating Leases (Detail)	Dec. 31, 2015USD ($)
Future Minimum Rental Payments For Operating Leases [Line Items]
2,016	$ 64,430
2,017	66,514
2,018	5,557
Total future minimum lease payments	$ 136,501

Future Minimum Lease Payments60

Future Minimum Lease Payments Under Capital Leases (Detail)	Dec. 31, 2015USD ($)
Future Minimum Lease Payments For Capital Leases [Line Items]
2,016	$ 4,778
2,017	4,380
Total net future minimum lease payments	9,158
Less: Amount representing interest	(1,235)
Present value of net minimum lease payments	$ 7,923

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - USD ($)	Jan. 12, 2016	Jun. 02, 2008	Oct. 21, 2015	Mar. 14, 2016
Subsequent Event [Line Items]
Debt Conversion, Converted Instrument, Shares Issued		1,962,338
Stock Award 2016 Plan [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period, Maximum Number				2,000,000
Common Stock, Capital Shares Reserved for Future Issuance				9,000,000
Convertible Notes Payable [Member]
Subsequent Event [Line Items]
Debt Conversion, Converted Instrument, Amount			$ 2,100,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Stock Issued During Period Shares New Issues	21,153,997
Subsequent Event [Member] | Convertible Notes Payable [Member]
Subsequent Event [Line Items]
Debt Conversion, Converted Instrument, Shares Issued	6,081,858
Subsequent Event [Member] | Convertible Notes, Accrued Interest [Member]
Subsequent Event [Line Items]
Debt Conversion, Converted Instrument, Amount	$ 28,652
Subsequent Event [Member] | Stock Purchase Agreement [Member]
Subsequent Event [Line Items]
Proceeds from Issuance of Common Stock	7,400,000
Debt Conversion, Converted Instrument, Amount	$ 2,100,000
Shares Issued, Price Per Share	$ 0.35
Subsequent Event [Member] | Stock Purchase Agreement [Member] | Minimum [Member]
Subsequent Event [Line Items]
Percentage of Liquidity Damages to Purchase Price of Units	1.00%
Subsequent Event [Member] | Stock Purchase Agreement [Member] | Maximum [Member]
Subsequent Event [Line Items]
Percentage of Liquidity Damages to Purchase Price of Units	10.00%